Thus, even though our findings did not identify a cardiovascular benefit among patients without established cardiovascular disease, additional evidence specifically targeting this population would be needed to conclude whether GLP1-RA or SGLT-2i drugs are effective or not for primary prevention of cardiovascular events. This evidence concerns the gene GLP1R and cardiovascular disorder.